An interventional study of Hysterectomy in Uterine Fibroids, Uterine Leiomyoma and Abnormal Uterine Bleeding, Unspecified, sponsored by Medical University of Graz. Completed at 3 sites in Austria. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-04-17.
Sponsored by Medical University of Graz · Not applicable, Interventional, and Treatment
Hysterectomy for benign indication is one of the most common surgical procedures in women. Numerous reviews and guidelines recommend the vaginal approach for benign hysterectomy, but the proportion of laparoscopic (and robotic) hysterectomies is increasing.
This study will compare a range of clinical and subjective outcomes of vaginal vs. total laparoscopic hysterectomy. Outcomes include operating time, postoperative recovery, return to work as well as cosmesis, quality of life and sexual health.
490 studies on the registry are indexed under Leiomyoma; 81 are open to participants now.
This study's enrollment of 100 is above the median of 62 across 345 interventional studies indexed under Leiomyoma.
Browse Leiomyoma studies →Medical University of Graz is the lead sponsor of 459 studies on the registry; 98 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Vaginal hysterectomy
Procedure: Hysterectomy
Laparoscopic hysterectomy
Procedure: Hysterectomy
Operating time (min.)
Operating time (min.)
Time frame: Surgery
Complications
Intraoperative and postoperative complications
Time frame: 6 weeks
Anesthesia time (min.)
Time frame: surgery
Quality of life
Time frame: 12 months
Sexual health
Time frame: 12 months
Return to work
Time frame: 3 months
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Graz